Tabernero, J., Strickler, J., Nakamura, Y., Shitara, K., Janjigian, Y., Barzi, A., … Marshall, J. (2022). P-156 MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress. In Annals of Oncology (Vol. 33, pp. S305–S306). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.04.246

Tabernero, J., J. Strickler, Y. Nakamura, K. Shitara, Y. Janjigian, A. Barzi, T. Bekaii-Saab, et al. “P-156 MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress.” In Annals of Oncology, 33:S305–6. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.04.246.

Tabernero J, Strickler J, Nakamura Y, Shitara K, Janjigian Y, Barzi A, et al. P-156 MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress. In: Annals of Oncology. Elsevier BV; 2022. p. S305–6.

Tabernero, J., et al. “P-156 MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S305–06. Crossref, doi:10.1016/j.annonc.2022.04.246.

Tabernero J, Strickler J, Nakamura Y, Shitara K, Janjigian Y, Barzi A, Bekaii-Saab T, Lenz H, Yoshino T, Siena S, Garrido-Mayor J, Ubowski M, Xie D, Marshall J. P-156 MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress. Annals of Oncology. Elsevier BV; 2022. p. S305–S306.